- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01083680
Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine
Post-marketing Observational Study to Evaluate the Safety and Efficacy of HUMIRA® (Adalimumab SC) for the Treatment of Moderate to Severe Crohn's Disease in Daily Clinical Practice
Przegląd badań
Status
Warunki
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Severe, active Crohn's Disease in patients with insufficient response to a complete and adequate therapy of glucocorticoid and/or immunosuppressive drug and/or hypersensitivity against such a therapy or in patients where such a therapy is contraindicated.
Exclusion Criteria:
- Hypersensitivity against the drug or one of the other ingredients.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
---|
Participants with Crohn's Disease (CD)
Participants with Crohn's Disease treated with adalimumab (HUMIRA®) in routine clinical practice.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) at Each Visit
Ramy czasowe: Months 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
The CDAI is a measure of clinical response and remission that was developed for use in clinical trials.
The CDAI includes 8 variables encompassing both patient-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables.
For symptoms scores, patients keep track of daily symptoms on a diary card, and the daily symptom scores are summed for the week.
Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score.
Higher CDAI scores indicate greater disease activity; 0 would the lower limit with no set upper limit.
The scale for the scores is as follows: < 150 to indicate remission, 150 - 219 to define mildly active disease, 220 - 450 to define moderately active disease, and > 450 to define severely active disease.
Negative changes indicate reductions (improvement) in disease activity.
|
Months 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
Percentage of Full Analysis Set (FAS) Participants in Each CDAI Disease Classification Over Time
Ramy czasowe: Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
The CDAI is a measure of clinical response and remission that was developed for use in clinical trials.
The CDAI includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables.
For symptoms scores, patients keep track of daily symptoms on a diary card, and the daily symptom scores are summed for the week.
Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score.
Higher CDAI scores indicate greater disease activity; there is no set upper limit.
The scale for the scores is as follows: < 150 to indicate remission, 150 - 219 to define mildly active disease, 220 - 450 to define moderately active disease, and > 450 to define severely active disease.
|
Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) at Each Visit in FAS Participants
Ramy czasowe: Months 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is an abbreviated version of the Inflammatory Bowel Disease (IBD) Questionnaire, a Health-related quality of life (HRQOL) assessment tool for patients with IBD.
The SIBDQ utilizes 10 items concerning patient well-being during the last 2 weeks, each of which is scored on a scale of 1 (poor HRQOL) to 7 (optimum HRQOL).
The individual sub scores are added to produce the total SIBDQ score.
SIBDQ scores range from 10 to 70 with higher values indicating better HRQOL.
Positive changes indicate reductions in disease activity.
|
Months 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
Percentage of Participants With Adverse Events (Excluding Serious Adverse Events)
Ramy czasowe: Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not the event is considered causally related to the use of the product. For more details on adverse events please see the AE section below. |
Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
4.Mean Harvey Bradshaw Index (HBI) in Full Analysis Set (FAS) Participants Over Time
Ramy czasowe: Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
The HBI is a simplified version of the CDAI; HBI scores correlate well with CDAI scores.
The HBI consists of 5 items encompassing patient-reported (well-being, symptoms)and objective (presence of abdominal mass or complications) variables.
Symptom scores are based on symptom status on the previous day rather than the total of 7 days as for the CDAI.
The total HBI score is the sum of the values for each of the five items.
Higher HBI scores indicate greater disease activity; 0 would the lower limit with no set upper limit.
Scores < 5 indicate remission, 5 - 7 indicate mild disease, 8 - 16 indicate moderate disease, and 16 indicate severe disease.
Each HBI unit is equivalent to approximately 27 CDAI units.
Higher scores indicate greater disease activity.
|
Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
Compliance With the Self-injection Via the Humira®-PEN
Ramy czasowe: Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
Adalimumab will be self-administered by participants using Humira®-PEN.
Analysis of compliance was not performed as outlined in the protocol.
|
Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Sandra Bloch, MD, AbbVie Deutschland GmbH & Co. KG, Medical Department
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- P10-278
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Choroba Crohna
-
Bambino Gesù Hospital and Research InstituteZakończonyCiężka otyłość dziecięca (BMI > 97° szt. -według wykresów BMI Centers for Disease Control and Prevention-) | Zmienione testy czynnościowe wątroby | Nietolerancja glikemicznaWłochy
-
Spero TherapeuticsZakończonyKompleks Mycobacterium Avium | Niegruźlicze Mycobacterium Pulmonary DiseaseStany Zjednoczone
-
Janssen Pharmaceutical K.K.RekrutacyjnyOporna na leczenie Mycobacterium Avium Complex-lung Disease (MAC-LD)Tajwan, Republika Korei, Japonia
-
Adelphi Values LLCBlueprint Medicines CorporationZakończonyBiałaczka z komórek tucznych (MCL) | Agresywna mastocytoza układowa (ASM) | SM w Assoc Clonal Hema Lineage Non-mast Cell Lineage Disease (SM-AHNMD) | Tląca się mastocytoza układowa (SSM) | Indolentna układowa mastocytoza (ISM) Podgrupa ISM w pełni zatrudnionaStany Zjednoczone